Difelikefalin

Synonyms: CR-845; FE-202845
Difelikefalin (CR-845; FE-202845) 是一种具有口服活性的外周作用型 κ 阿片受体 (kappa opioid receptor) 激动剂,可减轻急性肾损伤、减少少尿、维持尿液流量、抑制细胞因子表达、提高缺血/再灌注后内毒素血症的存活率、抑制瘙痒信号并具有神经调节止痒活性,可用于急性肾损伤、慢性肾脏病相关性瘙痒以及特应性皮炎的相关研究。
产品编号: MS-N84083 纯度: 99.98% CAS No.: 1024828-77-0 分子式: C36H53N7O6 分子量: 679.85
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Difelikefalin (CR-845; FE-202845) 是一种具有口服活性的外周作用型 κ 阿片受体 (kappa opioid receptor) 激动剂,可减轻急性肾损伤、减少少尿、维持尿液流量、抑制细胞因子表达、提高缺血/再灌注后内毒素血症的存活率、抑制瘙痒信号并具有神经调节止痒活性,可用于急性肾损伤、慢性肾脏病相关性瘙痒以及特应性皮炎的相关研究。

生物实验数据

生物活性 Difelikefalin (CR-845; FE-202845) is an orally active, peripherally acting kappa opioid receptor agonist that alleviates acute kidney injury, reduces oliguria, maintains urine flow, inhibits cytokine expression, improves survival in endotoxemia after ischemia/reperfusion, suppresses itch signaling, and exhibits neuromodulatory antipruritic activity, and it can be used in research related to acute kidney injury, chronic kidney disease-associated pruritus, and atopic dermatitis.
IC50 & Target

κ Opioid Receptor/KOR

 

IL-10

 

体外研究
(In Vitro)

Difelikefalin 在分离自 C57Bl/6J 小鼠肾脏的 KOR1 阳性肾间质细胞中,对 LPS 诱导的 TNF-α、CCL3 和 IL-10 mRNA 表达升高呈现无统计学意义的抑制趋势。
Difelikefalin 可优先激活小鼠中至大直径背根神经节神经元,且不会直接改变神经元对 Histamine (MS-J66916) 或 Chloroquine (MS-D84251) 等致痒原的反应。

体内研究
(In Vivo)

Difelikefalin (1 mg/kg;静脉注射;持续输注;2 小时) 可在正常麻醉大鼠中产生短暂的利尿作用,且不会改变其血压或脉搏率。
Difelikefalin (0.3-1.0 mg/kg;静脉注射;单次给药;LPS 处理前 1 小时) 可改善小鼠 LPS 诱导的脓毒症急性肾损伤模型中的肾小管流速。
Difelikefalin (0.3-1.0 mg/kg;静脉注射;单次给药;CLP 造模前 1 小时) 可改善 CLP 诱导的小鼠多微生物脓毒症相关性急性肾损伤模型中的肾小管流速。
Difelikefalin (0.3 mg/kg;静脉注射;单次给药;缺血/再灌注后第 1-5 天) 可将后续 LPS 诱导的小鼠脓毒性急性肾损伤的存活率提升至 80% 以上。
Difelikefalin (1.0 mg/kg;静脉注射;单次给药;LPS 处理前 1 小时) 可改善 LPS 诱导的小鼠脓毒症急性肾损伤模型中的肾小管流速,且该作用独立于肾神经支配。
Difelikefalin 可显著升高 LPS 诱导的脓毒症急性肾损伤小鼠的血浆 IL-10 水平。
Difelikefalin (0.5 mg/kg;腹腔注射;每日 2 次;连续 14 天) 可抑制小鼠中特应性皮炎相关瘙痒。
Difelikefalin (1.0 mg/kg;腹腔注射;单次给药) 可快速减轻小鼠中特应性皮炎相关的搔抓行为。

Animal Model: Sprague-Dawley (male, 7-10 weeks old, 250-350 g)
Dosage: 1 mg/kg
Administration: i.v.; continuous infusion; 2 hours
Result: Rapidly increased hourly urine volume.
Gradually subsided and became statistically insignificant 3 hours post-administration.
Showed no changes to blood pressure or pulse rate relative to baseline.
Animal Model: C57Bl/6J (male, 7-10 weeks old, 20-25 g)
Dosage: 0.3, 1.0 mg/kg
Administration: i.v.; single injection; 1 hour pre-LPS
Result: Elevated the 150-second Lucifer Yellow distal nephron delivery ratio from 0% to 64% at 0.3 mg/kg, and cut the proportion of unreached nephrons after 300 s from 95% to 21% at the same dose.
Raised the 0-150 s delivery percentage to 46% at 1.0 mg/kg while lowering the > 300 s unreached nephron fraction to 22%.
Mitigated LPS-triggered 6-hour urine volume decline significantly at 1.0 mg/kg.
Animal Model: C57Bl/6J (male, 7-10 weeks old, 20-25 g)
Dosage: 0.3, 1.0 mg/kg
Administration: i.v.; single injection; 1 hour pre-CLP
Result: Increased the percentage of distal nephrons reached by Lucifer Yellow within 150 s from 25% to a higher level at 1.0 mg/kg.
Reduced the percentage of nephrons unreached after 300 s from 71% at 1.0 mg/kg.
Did not improve tubular flow rate at 0.3 mg/kg.
Animal Model: C57Bl/6J (male, 7-10 weeks old, 20-25 g)
Dosage: 0.3 mg/kg
Administration: i.v.; single injections; days 1, 3, and 5 post-ischemia/reperfusion
Result: Increased the median survival time from 54 hours (control) to over 80% survival in the acute phase.
Enabled 5 of 8 surviving mice to live for more than 2 years with no visible abnormalities.
Animal Model: C57Bl/6J (male, 7-10 weeks old, 20-25 g)
Dosage: 1.0 mg/kg
Administration: i.v.; single injection; 1 hour pre-LPS
Result: Improved urine flow rate in both non-denervated and denervated mice, demonstrating the effect was independent of renal nerve input/output.
Animal Model: C57BL/6 (wild-type, aged 8-12 weeks, atopic dermatitis model via topical MC903 (MS-Q04527) treatment)
Dosage: 0.5 mg/kg
Administration: i.p.; twice daily; 14 days
Result: Markedly inhibited scratching behavior across day 0, day 4, day 8 and day 12.
Exerted no modulatory impact on AD-associated skin inflammation, with unaltered skin macroscopic morphology, ear thickness variation and abundance/activation of CD45+ immune cells, CD4+ T cells and group 2 innate lymphoid cells confirmed by histopathology.
Induced marginal transcriptomic alterations in ear skin identified by bulk RNA-sequencing.
Animal Model: C57BL/6 (wild-type, aged 8-12 weeks, atopic dermatitis model via topical MC903 (MS-Q04527) treatment)
Dosage: 1.0 mg/kg
Administration: i.p.; single dose
Result: Significantly reduced scratching bouts per 15 minutes 30 minutes after injection.
Clinical Trial
性状 固体
颜色 White to off-white

化学信息

分子量 679.85
分子式 C36H53N7O6
CAS No. 1024828-77-0
别名 CR-845; FE-202845

储存&溶解度

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (147.09 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : ≥ 100 mg/mL (147.09 mM)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO / H2O1 mM1.4709 mL7.3546 mL14.7091 mL36.7728 mL
5 mM0.2942 mL1.4709 mL2.9418 mL7.3546 mL
10 mM0.1471 mL0.7355 mL1.4709 mL3.6773 mL
15 mM0.0981 mL0.4903 mL0.9806 mL2.4515 mL
20 mM0.0735 mL0.3677 mL0.7355 mL1.8386 mL
25 mM0.0588 mL0.2942 mL0.5884 mL1.4709 mL
30 mM0.0490 mL0.2452 mL0.4903 mL1.2258 mL
40 mM0.0368 mL0.1839 mL0.3677 mL0.9193 mL
50 mM0.0294 mL0.1471 mL0.2942 mL0.7355 mL
60 mM0.0245 mL0.1226 mL0.2452 mL0.6129 mL
80 mM0.0184 mL0.0919 mL0.1839 mL0.4597 mL
100 mM0.0147 mL0.0735 mL0.1471 mL0.3677 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础